Megumu Saito

Dr. Megumu Saito

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
MMMitsuhiro Matsuda
Mitsuhiro Matsuda
YYYoshihiro Yamanaka
Yoshihiro Yamanaka
MUMaya Uemura
Maya Uemura
MOMitsujiro Osawa
Mitsujiro Osawa
MSMegumu Saito
Megumu Saito
CACantas Alev
Cantas Alev

3 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMasakatsu D. Yanagimachi
Masakatsu D. Yanagimachi
ANAkira Niwa
Akira Niwa
TTTakayuki Tanaka
Takayuki Tanaka
FHFumiko Honda-Ozaki
Fumiko Honda-Ozaki
SNSeiko Nishimoto
Seiko Nishimoto
MSMegumu Saito
Megumu Saito
Monocytic lineage cells (monocytes, macrophages and dendritic cells) play important roles in immune responses and are involved in various pathological conditions. The development of monocytic cells from human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) is of particular interest because it provides an unlimited cell source for clinical application and basic research on disease pathology. Although the methods for monocytic cell differentiation from ESCs/iPSCs using embryonic body or feeder co-culture systems have already been established, these methods depend on the use of xenogeneic materials and, therefore, have a relatively poor-reproducibility. Here, we established a robust and highly-efficient method to differentiate functional monocytic cells from ESCs/iPSCs under serum- and feeder cell-free conditions. This method produced 1.3×10 6 ±0.3×10 6 floating monocytes from approximately 30 clusters of ESCs/iPSCs 5–6 times per course of differentiation. Such monocytes could be differentiated into functional macrophages and dendritic cells. This method should be useful for regenerative medicine, disease-specific iPSC studies and drug discovery.

15 February 2008 in Blood
Verified
Journal Article
Open access
PDF file
MSMegumu Saito
Megumu Saito
RNRyuta Nishikomori
Ryuta Nishikomori
NKNaotomo Kambe
Naotomo Kambe
AFAkihiro Fujisawa
Akihiro Fujisawa
HTHideaki Tanizaki
Hideaki Tanizaki
TNTatsutoshi Nakahata
Tatsutoshi Nakahata
Cryopyrin-associated periodic syndrome (CAPS) is a spectrum of systemic autoinflammatory disorders in which the majority of patients have mutations in the cold-induced autoinflammatory syndrome (CIAS)1 gene. Despite having indistinguishable clinical features, some patients lack CIAS1 mutations by conventional nucleotide sequencing. We recently reported a CAPS patient with mosaicism of mutant CIAS1, and raised the possibility that CIAS1 mutations were overlooked in “mutation-negative” patients, due to a low frequency of mosaicism. To determine whether there were latent mutant cells in “mutation-negative” patients, we sought to identify mutation-associated biologic phenotypes of patients9 monocytes. We found that lipopolysaccharide selectively induced necrosis-like cell death in monocytes bearing CIAS1 mutations. Monocyte death correlated with CIAS1 up-regulation, was dependent on cathepsin B, and was independent of caspase-1. Cell death was intrinsic to CIAS1-mutated monocytes, was not mediated by the inflammatory milieu, and was independent of disease severity or anti–IL-1 therapy. By collecting dying monocytes after lipopolysaccharide treatment, we succeeded in enriching CIAS1-mutant monocytes and identifying low-level CIAS1-mosaicism in 3 of 4 “mutation-negative” CAPS patients. Our findings reveal a novel effect of CIAS1 mutations in promoting necrosis-like cell death, and demonstrate that CIAS1 mosaicism plays an important role in mutation-negative CAPS patients.

1 April 2015 in Stem Cell Reports
Verified
Journal Article
Open access
MYMichiko Yoshida
Michiko Yoshida
SKShiho Kitaoka
Shiho Kitaoka
NENaohiro Egawa
Naohiro Egawa
MYMayu Yamane
Mayu Yamane
RIRyunosuke Ikeda
Ryunosuke Ikeda
MSMegumu Saito
Megumu Saito
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by mutations of the survival of motor neuron 1 (SMN1) gene. In the pathogenesis of SMA, pathological changes of the neuromuscular junction (NMJ) precede the motor neuronal loss. Therefore, it is critical to evaluate the NMJ formed by SMA patients' motor neurons (MNs), and to identify drugs that can restore the normal condition. We generated NMJ-like structures using MNs derived from SMA patient-specific induced pluripotent stem cells (iPSCs), and found that the clustering of the acetylcholine receptor (AChR) is significantly impaired. Valproic acid and antisense oligonucleotide treatment ameliorated the AChR clustering defects, leading to an increase in the level of full-length SMN transcripts. Thus, the current in vitro model of AChR clustering using SMA patient-derived iPSCs is useful to dissect the pathophysiological mechanisms underlying the development of SMA, and to evaluate the efficacy of new therapeutic approaches.

27 October 2016 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
YKYuri Kawasaki
Yuri Kawasaki
HOHirotsugu Oda
Hirotsugu Oda
JIJun Ito
Jun Ito
ANAkira Niwa
Akira Niwa
TTTakayuki Tanaka
Takayuki Tanaka
MSMegumu Saito
Megumu Saito
Objective: To elucidate the genetic background of a patient with neonatal‐onset multisystem inflammatory disease (NOMID) with no NLRP3 mutation.Methods: A Japanese male child diagnosed as having NOMID was studied. The patient did not have any NLRP3 mutation, even as low‐frequency mosaicism. We performed whole‐exome sequencing on the patient and his parents. Induced pluripotent stem cells (iPSCs) were established from the patient's fibroblasts. The iPSCs were then differentiated into monocyte lineage to evaluate the cytokine profile.Results: We established multiple iPSC clones from a patient with NOMID and incidentally found that the phenotypes of monocytes from iPSC clones were heterogeneous and could be grouped into disease and normal phenotypes. Because each iPSC clone was derived from a single somatic cell, we hypothesized that the patient had somatic mosaicism of an interleukin‐1β–related gene. Whole‐exome sequencing of both representative iPSC clones and the patient's blood revealed a novel heterozygous NLRC4 mutation, p.T177A (c.529A>G), as a specific mutation in diseased iPSC clones. Knockout of the NLRC4 gene using the clustered regularly interspaced short palindromic repeat/Cas9 system in a mutant iPSC clone abrogated the pathogenic phenotype.Conclusion: Our findings indicate that the patient has somatic mosaicism of a novel NLRC4 mutation. To our knowledge, this is the first case showing that somatic mutation of NLRC4 causes autoinflammatory symptoms compatible with NOMID. The present study demonstrates the significance of prospective genetic screening combined with iPSC‐based phenotype dissection for individualized diagnoses.

19 September 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
CLChuang-Yu Lin
Chuang-Yu Lin
MYMichiko Yoshida
Michiko Yoshida
LLLi-Tzu Li
Li-Tzu Li
AIAkihiro Ikenaka
Akihiro Ikenaka
SOShiori Oshima
Shiori Oshima
MSMegumu Saito
Megumu Saito
The control of voluntary skeletal muscle contraction relies on action potentials, which send signals from the motor neuron through the neuromuscular junction (NMJ). Although dysfunction of the NMJ causes various neuromuscular diseases, a reliable in vitro system for disease modeling is currently unavailable. Here, we present a potentially novel 2-step, self-organizing approach for generating in vitro human NMJs from human induced pluripotent stem cells. Our simple and robust approach results in a complex NMJ structure that includes functional connectivity, recapitulating in vivo synapse formation. We used these in vitro NMJs to model the pathological features of spinal muscular atrophy, revealing the developmental and functional defects of NMJ formation and NMJ-dependent muscular contraction. Our differentiation system is therefore useful for investigating and understanding the physiology and pathology of human NMJs.